
Union Therapeutics has previously in-licensed medicinal rights, but the company's deal with Leo Pharma for the drug orismilast still breaks new ground for the Danish biotech group, established in 2011 – not only because the agreement, with a combined value of DKK 1.3 billion, is the firm's largest to date.
"This is a very exciting step for us, as it supplements our existing portfolio of programs and drugs very well," Union Therapeutics Chief Financial Officer Morten Boesen tells MedWatch.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app